Cargando…

The translational challenge in Chagas disease drug development

Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. There is an urgent need for safe, effective, and accessible new treatments since the currently approved drugs have serious limitations. Drug development for Chagas disease has historically been hampere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kratz, Jadel M, Gonçalves, Karolina R, Romera, Lavínia MD, Moraes, Carolina Borsoi, Bittencourt-Cunha, Paula, Schenkman, Sergio, Chatelain, Eric, Sosa-Estani, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128742/ https://www.ncbi.nlm.nih.gov/pubmed/35613156 http://dx.doi.org/10.1590/0074-02760200501

Ejemplares similares

Congenital Chagas disease: an update
por: Carlier, Yves, et al.
Publicado: (2015)

Therapy of Chagas Disease: Implications for Levels of Prevention
por: Sosa-Estani, Sergio, et al.
Publicado: (2012)

Integrated control of Chagas disease for its elimination as public health problem - A Review
por: Sosa-Estani, Sergio, et al.
Publicado: (2015)

The Need of a Neonatal Preparation for Chagas Disease
por: Sosa-Estani, Sergio, et al.
Publicado: (2005)

Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection
por: Franco, Caio Haddad, et al.
Publicado: (2019)

Translational challenges of animal models in Chagas disease drug development: a review
por: Chatelain, Eric, et al.
Publicado: (2015)

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development
por: Moraes, Carolina B., et al.
Publicado: (2014)

A new patient registry for Chagas disease
por: Hotez, Peter, et al.
Publicado: (2020)

The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform
por: Maguire, Brittany J., et al.
Publicado: (2021)

Critical analysis of Chagas disease treatment in different countries
por: Mendes, Fernanda de Souza Nogueira Sardinha, et al.
Publicado: (2022)

Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women
por: Carlier, Yves, et al.
Publicado: (2011)

Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation
por: Machado, Fabricio Castro, et al.
Publicado: (2018)

Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021
por: de Oliveira, Ramon G., et al.
Publicado: (2021)

Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas
por: Fabbro, Diana L., et al.
Publicado: (2014)

Cultural barriers to effective communication between Indigenous communities and health care providers in Northern Argentina: an anthropological contribution to Chagas disease prevention and control
por: Dell’Arciprete, Ana, et al.
Publicado: (2014)

The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America
por: Picado, Albert, et al.
Publicado: (2018)

Chagas disease control-surveillance in the Americas: the multinational initiatives and the practical impossibility of interrupting vector-borne Trypanosoma cruzi transmission
por: de Arias, Antonieta Rojas, et al.
Publicado: (2022)

Chagas disease research and development: Is there light at the end of the tunnel?
por: Chatelain, Eric
Publicado: (2016)

Text message interventions for follow up of infants born to mothers positive for Chagas disease in Tucumán, Argentina: a feasibility study
por: Cormick, Gabriela, et al.
Publicado: (2015)

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
por: Franco, Caio H., et al.
Publicado: (2020)

Human Trypanosoma cruzi chronic infection leads to individual level steady-state parasitemia: Implications for drug-trial optimization in Chagas disease
por: De Salazar, Pablo M., et al.
Publicado: (2022)

WHF IASC Roadmap on Chagas Disease
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

New Biomarker in Chagas Disease: Extracellular Vesicles Isolated from Peripheral Blood in Chronic Chagas Disease Patients Modulate the Human Immune Response
por: Madeira, Rafael Pedro, et al.
Publicado: (2021)

COVID-19: Implications for People with Chagas Disease
por: Zaidel, Ezequiel José, et al.
Publicado: (2020)

Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment
por: Porrás, Analía I., et al.
Publicado: (2015)

Highlights of the XXI annual meeting of the Brazilian Society of Protozoology, the XXXII annual meeting on Basic Research in Chagas' disease & an international symposium on vesicle trafficking in parasitic Protozoa – 7 to 9 November 2005, Caxambu, Minas Gerais, Brazil
por: Shaw, Jeffrey, et al.
Publicado: (2006)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis
por: Ciapponi, Agustín, et al.
Publicado: (2020)

Estrategia para mejorar el acceso al tratamiento etiológico para la enfermedad de Chagas en el primer nivel de atención en Argentina
por: Klein, Karen, et al.
Publicado: (2017)

Chagas Disease and Heart Failure: An Expanding Issue Worldwide
por: Martinez, Felipe, et al.
Publicado: (2019)

Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus
por: Alonso-Padilla, Julio, et al.
Publicado: (2020)

Comment on “The translational challenge in Chagas disease drug development” by Kratz et al.
por: De Rycker, Manu
Publicado: (2022)

GCN2-Like Kinase Modulates Stress Granule Formation During Nutritional Stress in Trypanosoma cruzi
por: Malvezzi, Amaranta Muniz, et al.
Publicado: (2020)

Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study
por: Colantonio, Lisandro D., et al.
Publicado: (2016)

Higher congenital transmission rate of Trypanosoma cruzi associated with family history of congenital transmission
por: Danesi, Emmaría, et al.
Publicado: (2020)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Natural products modulating the hERG channel: heartaches and hope
por: Kratz, Jadel M., et al.
Publicado: (2017)

Challenges in Chagas Disease Drug Development
por: Francisco, Amanda F., et al.
Publicado: (2020)

Immunization with a Trypanosoma cruzi cyclophilin-19 deletion mutant protects against acute Chagas disease in mice
por: Jha, Bijay Kumar, et al.
Publicado: (2023)

Trypanosoma cruzi loop-mediated isothermal amplification (Trypanosoma cruzi Loopamp) kit for detection of congenital, acute and Chagas disease reactivation
por: Besuschio, Susana A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9uopht101c454tq4far893mc05